BFA
ALDX icon

BlackRock Fund Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

BlackRock Fund Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$146K Buy
27,319
+6,741
+33% +$39.5K ﹤0.01% 3508
2016
Q3 		$161K Sell
20,578
-52
-0.3% -$318 ﹤0.01% 3517
2016
Q2 		$117K Buy
20,630
+19,621
+1,945% +$110K ﹤0.01% 3625
2016
Q1 		$4K Buy
1,009
+228
+29% +$1.1K ﹤0.01% 4113
2015
Q4 		$5K Buy
+781
New +$5.25K ﹤0.01% 4121

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Fund Advisors's ALDX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Aldeyra Therapeutics (ALDX) stake by 33% in Q4 2016, buying an estimated $39.5K and bringing the position to 27,319 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #3508.

BlackRock Fund Advisors first reported a position in ALDX in Q4 2015 and has held it in 5 quarters since. The position peaked at $161K in Q3 2016. 20 funds tracked by Wall St. Rank hold ALDX as of Q4 2016.

  • BlackRock Fund Advisors held 27,319 shares of Aldeyra Therapeutics worth $146K as of Q4 2016.
  • BlackRock Fund Advisors bought 6,741 Aldeyra Therapeutics shares in Q4 2016, an estimated $39.5K.
  • Aldeyra Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3508 holding.
  • BlackRock Fund Advisors first reported a position in Aldeyra Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Fund Advisors's Aldeyra Therapeutics position peaked at $161K in Q3 2016.
  • 20 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.